Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (151-160 of 685) with videos related to

Pageof 69
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer DrugsDiogo D G Bugano, Kenneth Hess, Denis L F Jardim, et al.
European Journal of Immunology|September 19, 2019
Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumorsCaitlin A Creasy, Marie-Andrée Forget, Gopal Singh, et al.
Drug Discovery Today|July 8, 2015
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platformAmber Johnson, Jia Zeng, Ann M Bailey, et al.
Plos One|May 9, 2018
Cancer driver mutation prediction through Bayesian integration of multi-omic dataZixing Wang, Kwok-Shing Ng, Tenghui Chen, et al.
NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Annals of Surgical Oncology|January 18, 2023
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast CancerKelly K Hunt, Vera J Suman, Hannah F Wingate, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Journal of the American College of Surgeons|November 6, 2012
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient populationMin Yi, Henry M Kuerer, Elizabeth A Mittendorf, et al.
Journal of Hepatology|March 30, 2026
Global patterns of mutational profiles in biliary tract cancerYan Zhu, Jason A Wu, Dengyong Zhang, et al.
Annals of Surgical Oncology|March 13, 2009
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservationJudy C Boughey, Jamie Wagner, Betsy J Garrett, et al.
Pageof 69

Showing results (151-160 of 685) with videos related to

Sort By:
Pageof 69
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer DrugsDiogo D G Bugano, Kenneth Hess, Denis L F Jardim, et al.
European Journal of Immunology|September 19, 2019
Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumorsCaitlin A Creasy, Marie-Andrée Forget, Gopal Singh, et al.
Drug Discovery Today|July 8, 2015
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platformAmber Johnson, Jia Zeng, Ann M Bailey, et al.
Plos One|May 9, 2018
Cancer driver mutation prediction through Bayesian integration of multi-omic dataZixing Wang, Kwok-Shing Ng, Tenghui Chen, et al.
NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Annals of Surgical Oncology|January 18, 2023
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast CancerKelly K Hunt, Vera J Suman, Hannah F Wingate, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Journal of the American College of Surgeons|November 6, 2012
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient populationMin Yi, Henry M Kuerer, Elizabeth A Mittendorf, et al.
Journal of Hepatology|March 30, 2026
Global patterns of mutational profiles in biliary tract cancerYan Zhu, Jason A Wu, Dengyong Zhang, et al.
Annals of Surgical Oncology|March 13, 2009
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservationJudy C Boughey, Jamie Wagner, Betsy J Garrett, et al.
Pageof 69